TY - JOUR AU - Keystone, E. C. PY - 2003 DA - 2003// TI - Abandoned therapies and unpublished trials in rheumatoid arthritis JO - Curr Opin Rheumatol VL - 15 UR - https://doi.org/10.1097/00002281-200305000-00012 DO - 10.1097/00002281-200305000-00012 ID - Keystone2003 ER - TY - JOUR AU - Moreland, L. W. AU - Alten, R. AU - Van den Bosch, F. AU - Appelboom, T. AU - Leon, M. AU - Emery, P. AU - Cohen, S. AU - Luggen, M. AU - Shergy, W. AU - Nuamah, I. PY - 2002 DA - 2002// TI - Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion JO - Arthritis Rheum VL - 46 UR - https://doi.org/10.1002/art.10294 DO - 10.1002/art.10294 ID - Moreland2002 ER - TY - JOUR AU - Kremer, J. M. AU - Westhovens, R. AU - Leon, M. AU - Di Giorgio, E. AU - Alten, R. AU - Steinfeld, S. AU - Russell, A. AU - Dougados, M. AU - Emery, P. AU - Nuamah, I. F. PY - 2003 DA - 2003// TI - Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig JO - N Engl J Med VL - 349 UR - https://doi.org/10.1056/NEJMoa035075 DO - 10.1056/NEJMoa035075 ID - Kremer2003 ER - TY - JOUR AU - Jenkins, M. K. AU - Taylor, P. S. AU - Norton, S. D. AU - Urdahl, K. B. PY - 1991 DA - 1991// TI - CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells JO - J Immunol VL - 147 ID - Jenkins1991 ER - TY - JOUR AU - Salomon, B. AU - Bluestone, J. A. PY - 2001 DA - 2001// TI - Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation JO - Annu Rev Immunol VL - 19 UR - https://doi.org/10.1146/annurev.immunol.19.1.225 DO - 10.1146/annurev.immunol.19.1.225 ID - Salomon2001 ER - TY - JOUR AU - Verwilghen, J. AU - Lovis, R. AU - De Boer, M. AU - Linsley, P. S. AU - Haines, G. K. AU - Koch, A. E. AU - Pope, R. M. PY - 1994 DA - 1994// TI - Expression of functional B7 and CTLA4 on rheumatoid synovial T cells JO - J Immunol VL - 153 ID - Verwilghen1994 ER - TY - JOUR AU - Karandikar, N. J. AU - Vanderlugt, C. L. AU - Walunas, T. L. AU - Miller, S. D. AU - Bluestone, J. A. PY - 1996 DA - 1996// TI - CTLA-4: a negative regulator of autoimmune disease JO - J Exp Med VL - 184 UR - https://doi.org/10.1084/jem.184.2.783 DO - 10.1084/jem.184.2.783 ID - Karandikar1996 ER - TY - JOUR AU - Walunas, T. L. AU - Bakker, C. Y. AU - Bluestone, J. A. PY - 1996 DA - 1996// TI - CTLA-4 ligation blocks CD28-dependent T cell activation JO - J Exp Med VL - 183 UR - https://doi.org/10.1084/jem.183.6.2541 DO - 10.1084/jem.183.6.2541 ID - Walunas1996 ER - TY - JOUR AU - Tang, Q. AU - Henriksen, K. J. AU - Boden, E. K. AU - Tooley, A. J. AU - Ye, J. AU - Subudhi, S. K. AU - Zheng, X. X. AU - Strom, T. B. AU - Bluestone, J. A. PY - 2003 DA - 2003// TI - Cutting Edge: CD28 controls peripheral homeostasis of CD4+, CD25+ Regulatory T cells JO - J Immunol VL - 171 UR - https://doi.org/10.4049/jimmunol.171.7.3348 DO - 10.4049/jimmunol.171.7.3348 ID - Tang2003 ER - TY - JOUR AU - Linsley, P. S. AU - Brady, W. AU - Urnes, M. AU - Grosmaire, L. S. AU - Damle, N. K. AU - Ledbetter, J. A. PY - 1991 DA - 1991// TI - CTLA-4 is a second receptor for the B cell activation antigen B7 JO - J Exp Med VL - 174 UR - https://doi.org/10.1084/jem.174.3.561 DO - 10.1084/jem.174.3.561 ID - Linsley1991 ER - TY - JOUR AU - Walunas, T. L. AU - Bluestone, J. A. PY - 1998 DA - 1998// TI - CTLA-4 regulates tolerance induction and T cell differentiation in vivo JO - J Immunol VL - 160 ID - Walunas1998 ER - TY - JOUR AU - Finck, B. K. AU - Linsley, P. S. AU - Wofsy, D. PY - 1994 DA - 1994// TI - Treatment of murine lupus with CTLA4Ig JO - Science VL - 265 UR - https://doi.org/10.1126/science.7520604 DO - 10.1126/science.7520604 ID - Finck1994 ER - TY - JOUR AU - Perrin, P. J. AU - Scott, D. AU - Quigley, L. AU - Albert, P. S. AU - Feder, O. AU - Gray, G. S. AU - Abe, R. AU - June, C. H. AU - Racke, M. K. PY - 1995 DA - 1995// TI - Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis JO - J Immunol VL - 154 ID - Perrin1995 ER - TY - JOUR AU - Cross, A. H. AU - Girard, T. J. AU - Giacoletto, K. S. AU - Evans, R. J. AU - Keeling, R. M. AU - Lin, R. F. AU - Trotter, J. L. AU - Karr, R. W. PY - 1995 DA - 1995// TI - Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation JO - J Clin Invest VL - 95 UR - https://doi.org/10.1172/JCI117982 DO - 10.1172/JCI117982 ID - Cross1995 ER - TY - JOUR AU - Girvin, A. M. AU - Dal Canto, M. C. AU - Rhee, L. AU - Salomon, B. AU - Sharpe, A. AU - Bluestone, J. A. AU - Miller, S. D. PY - 2000 DA - 2000// TI - A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade JO - J Immunol VL - 164 UR - https://doi.org/10.4049/jimmunol.164.1.136 DO - 10.4049/jimmunol.164.1.136 ID - Girvin2000 ER - TY - JOUR AU - Knoerzer, D. B. AU - Karr, R. W. AU - Schwartz, B. D. AU - Mengle-Gaw, L. J. PY - 1995 DA - 1995// TI - Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig JO - J Clin Invest VL - 96 UR - https://doi.org/10.1172/JCI118146 DO - 10.1172/JCI118146 ID - Knoerzer1995 ER - TY - JOUR AU - Daikh, D. I. AU - Wofsy, D. PY - 2001 DA - 2001// TI - Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide JO - J Immunol VL - 166 UR - https://doi.org/10.4049/jimmunol.166.5.2913 DO - 10.4049/jimmunol.166.5.2913 ID - Daikh2001 ER - TY - JOUR AU - Tada, Y. AU - Nagasawa, K. AU - Ho, A. AU - Morito, F. AU - Ushiyama, O. AU - Suzuki, N. AU - Ohta, H. AU - Mak, T. W. PY - 1999 DA - 1999// TI - CD28-deficient mice are highly resistant to collagen-induced arthritis JO - J Immunol VL - 162 ID - Tada1999 ER - TY - JOUR AU - Pawlik, A. AU - Ostanek, L. AU - Brzosko, I. AU - Brzosko, M. AU - Masiuk, M. AU - Machalinski, B. AU - Gawronska-Szklarz, B. PY - 2003 DA - 2003// TI - The expansion of CD4+ CD28-T cells in patients with rheumatoid arthritis JO - Arthritis Res Ther VL - 5 UR - https://doi.org/10.1186/ar766 DO - 10.1186/ar766 ID - Pawlik2003 ER - TY - STD TI - Weinblatt M, Schiff M, Goldman M, Kremer J, Breazna A, Becker JC: A pilot, multi-center, randomized, double-blind, placebo controlled [study] of a co-stimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis [abstract]. Arthritis Rheum. 2002, S204-Suppl ID - ref20 ER - TY - STD TI - Emery P, Russell A, Kremer J, Williams GR, Li T, Nuamah I, Becker JC, Weisman MH: Improvement in health-related quality of life with treatment of CTLA4Ig (BMS-188667), a selective co-stimulation modulator, over one year in patients with active rheumatoid arthritis using methotrexate [abstract]. Arthritis Rheum. 2003, S4-Suppl ID - ref21 ER - TY - CHAP AU - Emery, P. AU - Westhovens, R. AU - Moreland, L. AU - Nuamah, I. AU - Aranda, R. AU - Becker, J. AU - Kremer, J. PY - 2003 DA - 2003// TI - CTLA4Ig (BMS-188667) in a phase IIb, multi-center, randomized, double-blind, placebo controlled study in rheumatoid arthritis patients receiving methotrexate showed correlation between the clinical response and key biomarkers [abstract] BT - Presented at: European League Against Rheumatism Annual Meeting, Lisbon, Portugal ID - Emery2003 ER - TY - STD TI - Kremer J, Shergy W, Tindall E, Aranda R, Nuamah I, Zhou Y, Becker JC: Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum. 2004, S182-Suppl ID - ref23 ER - TY - STD TI - Dougados M, Weswthovens R, St Clair EW, Aranda R, Nuamah I, Zhou Y, Vratsanos G, Becker JC: Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate [abstract]. Arthritis Rheum. 2004, S185-Suppl ID - ref24 ER - TY - STD TI - Moreland L, Weisman M, Alten R, Aranda R, Zhou Y, Wu K, Nuamah I, Becker JC: Abatacept (CTLA4Ig) in combination with methotrexate for the treatment of rheumatoid arthritis: favorable safety and tolerability profile sustained over 2 years [abstract]. Arthritis Rheum. 2004, S563-Suppl ID - ref25 ER - TY - CHAP AU - Kremer, J. AU - Westhovens, R. AU - Moreland, L. AU - Emery, P. AU - Russell, A. AU - Ge, Z. AU - Aranda, R. AU - Becker, J. C. PY - 2004 DA - 2004// TI - Efficacy and safety of the selective co-stimulation modulator abatacept with methotrexate for treating rheumatoid arthritis: 1-year clinical and radiographic results from the phase III AIM (Abatacept in INadequate responders to Methotrexate) trial [abstract] BT - Presented at: American College of Rheumatology Annual Scientific Meeting, San Antonio, TX ID - Kremer2004 ER - TY - CHAP AU - Genovese, M. C. AU - Luggen, M. AU - Schiff, M. AU - Sherrer, Y. AU - Nuamah, I. AU - Aranda, R. AU - Becker, J. C. AU - Dougados, M. PY - 2004 DA - 2004// TI - Efficacy and safety of abatacept (CTLA4Ig), a selective co-stimulation modulator, in rheumatoid arthritis patients not responding adequately to anti-TNF-a[ED:alpha] therapy: results of the phase III ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate responders) trial [abstract] BT - Presented at: American College of Rheumatology Annual Scientific Meeting, San Antonio, TX ID - Genovese2004 ER -